The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
Sponsor: Exegi Pharma, LLC
Listed as NCT05090267, this NA trial focuses on Cognition and Gut Microbiome and remains actively recruiting participants. Sponsored by Exegi Pharma, LLC, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Jul 2025 — Present [monthly]
Recruiting NA
-
Sep 2024 — Jul 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
-
Sep 2022 — Jun 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Mar 2022 — Sep 2022 [monthly]
Not Yet Recruiting NA
-
Nov 2021 — Mar 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Exegi Pharma, LLC
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Soterix Medical
- University of Florida
- University of Louisville
- University of Miami
For direct contact, visit the study record on ClinicalTrials.gov .